Methodology and challenges to recruitment to a randomized, double-blind, placebo-controlled trial of oral DHEA in postmenopausal women

Journal of Women's Health

Volumn 17, Issue 10, 2008, Pages 1559-1565

  Panjari, Mary ^a   Bell, Robin ^a   Adams, Jenny ^a   Morrow, Corallee ^a   Papalia, Mary Anne ^a   Astbury, Jill ^b   Davis, Susan R ^a  

^a ALFRED HOSPITAL   (Australia)

^b VICTORIA UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PRASTERONE;

ACNE; ADULT; ADVERTIZING; AGED; ALOPECIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL RESEARCH; CLINICAL TRIAL; CLITORIS HYPERTROPHY; COMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HIRSUTISM; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MASS MEDIUM; METHODOLOGY; OILY SKIN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUBJECT; SCREENING; SIDE EFFECT; TIME; VOICE CHANGE; WOMEN'S HEALTH;

AGED; AUSTRALIA; DEHYDROEPIANDROSTERONE; DOUBLE-BLIND METHOD; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LIBIDO; MIDDLE AGED; PATIENT SELECTION; PLACEBOS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SOCIOECONOMIC FACTORS; WOMEN'S HEALTH;

EID: 57349178539     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2007.0732     Document Type: Article

References (35)

1. Puffer S, Torgerson D. Recruitment difficulties in randomized controlled trials. Controlled Clin Trials 2003;24:S214-S215.
2. Watson JM, Torgerson DJ. Increasing recruitment to randomised trials: A review of randomised controlled trials. BMC Med Res Methodology 2006;6:34.
3. Mapstone J, Elbourne D, Roberts I. Strategies to improve recruitment to research studies. Cochrane Database Systematic Rev 2007;18:MR000013.Review.
4. Davis SR, Goldstat R, Papalia MA, et al. Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: A randomized placebo-controlled trial. Menopause 2006;13:37-45.
5. Davis SR, Davison SL, Wilson S, Shepherd J, Lawton B. Intranasal versus transdermal matrix oestrogen replacement in Australasian women. Maturitas 2005;51:163-171.
6. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997;337:595-601.
7. Maki PM, Gast MJ, Vieweg AJ, Burriss SW, Yaffe K. Hormone therapy in menopausal women with cognitive complaints: A randomized, double-blind trial. Neurology 2007;69:1322-1330.
8. McManus P, Mant A, Mitchell P, et al. Recent trends in the use of anti-depressant drugs in Australia. Med J Aust 2000;173:458-461.
9. Fedor-Freybergh P. The influence of estrogens on the well-being and mental performance in climacteric and postmenopausal women. Acta Obstet Gynaecol Scand 1977;64:1-30.
10. Dupuy H. The psychological general well-being (PGWB) index. In: Wenger N, et al., eds. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq Publishing, 1984:170-183.
11. Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire. Maturitas 2005;50:209-221.
12. Goldstat R, Briganti E, Tran J, Wolfe R, Davis S. Transdermal testosterone improves mood, well-being and sexual function in premenopausal women. Menopause 2003;10:390-398.
13. Davis SR, van der Mooren MJ, van Lunsen RHW, et al. The efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Menopause 2006;13:387-396.
14. Shifren J, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: Results from the INTIMATE NM1 study. Menopause 2006;13:770-779.
15. Davis S, Papalia M-A, Norman R, et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treatment of decreased sexual satisfaction in premenopausal women: A placebo-controlled randomized, dose-ranging study. Ann of Intern Med 2008;148:569-577.
16. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstet Gynecol 2005;105:944-952.
17. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582-1589.
18. Davis S, Studd J, Bouchard C, et al. The effect of a testosterone transdermal system on hypoactive sexual desire disorder in postmenopausal women not receiving systemic estrogen therapy, The Aphrodite Study. Presented at the 88th Annual Meeting of The Endocrine Society. Boston, MA, 2006.
19. Rossouw J, Anderson G, Prentice R, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-333.
20. Beral V: Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the million women study. Lancet 2003;362:419-427.
21. Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-1232.
22. Menon U, Burnell M, Sharma A, et al. Decline in use of hormone therapy among postmenopausal women in the United Kingdom. Menopause 2007;14:462-467.
23. Haas JS, Miglioretti DL, Geller B, et al. Average household exposure to newspaper coverage about the harmful effects of hormone therapy and population-based declines in hormone therapy use. J Gen Intern Med 2007;22:68-73.
24. Burger HG. Hormone therapy in the WHI era. Aust NZ J Obstet Gynaecol 2006;46:84-91.
25. Baulieu E, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci 2000;97:4279-4284.
26. Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 1997;82:2363-2367.
27. Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. 1994;78:1360-1367.
28. Hirshman E, Merritt P, Wang CC, et al. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Hormones Behav 2004;45:144-155.
29. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry 1999;45:1533-1541.
30. Schmidt PJ, Daly RC, Bloch M, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005;62:154-162.
31. Hackbert L, Heiman J. Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women. J Womens Health Gend Based Med 2002;11:155.
32. Barnhart KT, Freeman E, Grisso JA, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999;84:3896-3902.
33. von Muhlen D, Laughlin GA, Kritz-Silverstein D, Barrett-Connor E. The dehydroepiandrosterone and wellness (DAWN) study: Research design and methods. Contemp Clin Trials 2007;28:153-168.
34. Australian Bureau of Statistics, Catalogue number 2004.0. Community Profile Series. 2006 Census of Population and Housing. Count of persons by age and sex based on place of usual residence (Melbourne).
35. Nijland E, Davis S, Laan E, Schultz WW. Female sexual satisfaction and pharmaceutical intervention: A critical review of the drug intervention studies in female sexual dysfunction. J Sex Med 2006;3:763-777.